Metoprolol Shortage: What Providers and Prescribers Need to Know in 2026

Metoprolol is among the most prescribed cardiovascular medications in the United States, used daily by millions of patients for hypertension, heart failure, angina, and arrhythmia management. While it is not in a declared national shortage as of 2026, clinicians should be aware of the supply chain dynamics affecting this class of medication and have a clear plan for patients who encounter stocking difficulties.

Current FDA Shortage Status

The FDA Drug Shortage Database does not list oral metoprolol tartrate or metoprolol succinate as currently in shortage. Metoprolol is manufactured by numerous generic pharmaceutical companies (including Sun Pharma, Amneal, Mylan/Viatris, and others), providing meaningful supply redundancy.

However, the IV formulation of metoprolol tartrate (1 mg/mL injection, used in acute MI management) has historically been more vulnerable to shortage conditions. Clinicians in hospital settings should remain aware of hospital formulary status for the IV form.

Why Localized Metoprolol Stock Issues Occur

Patients may report difficulty obtaining specific metoprolol strengths for several reasons:

• Generic manufacturer transitions: When a pharmacy chain switches generic supplier contracts, brief gaps can occur as new stock is integrated.
• API sourcing disruptions: Most metoprolol API is manufactured overseas. Regulatory actions at overseas facilities or shipping disruptions can create temporary supply constraints.
• Strength-specific shortfalls: Less common strengths (e.g., 37.5 mg, 75 mg of tartrate) may be stocked in smaller quantities at retail pharmacies, making them more susceptible to depletion.
• Formulation confusion: Tartrate and succinate are not interchangeable. A pharmacy with succinate in stock cannot automatically substitute for a tartrate prescription, creating perceived shortfalls.

Clinical Decision-Making: When to Switch Formulations or Agents

If a patient cannot obtain their prescribed metoprolol formulation, the following clinical considerations apply:

• Tartrate-to-succinate switch (or vice versa): This requires a new prescription specifying the alternate form and appropriate dose conversion. Note that succinate is approved for HFrEF; tartrate is not. Do not switch formulations for heart failure patients without confirming the indication is appropriate for the new form.
• Switch to bisoprolol: A highly cardioselective beta-1 blocker taken once daily. AHA-listed as a preferred agent for HFrEF (with survival data from the CIBIS-II trial). Typical starting dose 1.25–5 mg once daily, titrating to 10 mg/day.
• Switch to carvedilol: Non-selective beta-blocker with alpha-1 activity. Preferred by some guidelines for HFrEF, especially in patients where additional BP lowering is desired. Avoid in patients with significant asthma or COPD.
• Switch to atenolol: Cardioselective, once-daily, renally excreted. May be preferable for patients experiencing CNS side effects with metoprolol. Not recommended in pregnancy (Category D) or heart failure.

Key Prescribing Points When Transitioning

Regardless of which alternative you choose, observe these principles when transitioning a patient off metoprolol:

1. Avoid abrupt discontinuation. Taper metoprolol over 1-2 weeks when possible, particularly in patients with coronary artery disease or angina.
2. Monitor hemodynamics. Heart rate and blood pressure should be checked after any switch, particularly in heart failure or post-MI patients.
3. Document the indication. The indication determines which agents are appropriate substitutes. Heart failure patients cannot simply receive any beta-blocker — only AHA-approved HFrEF agents (metoprolol succinate, carvedilol, bisoprolol).
4. Review drug interactions. Metoprolol is metabolized by CYP2D6; if a patient is on a CYP2D6 inhibitor (e.g., fluoxetine, paroxetine, bupropion), they may be on a higher-than-expected effective dose. An alternative beta-blocker may have a different interaction profile.

Counseling Patients Who Report Supply Difficulty

When a patient contacts your office reporting they cannot find metoprolol, the following protocol is recommended:

1. Determine current supply. Ask how many days of medication remain. If >5 days, there is time to locate stock. If <2 days, treat as urgent.
2. Recommend medfinder. Direct the patient to medfinder.com, which calls pharmacies on their behalf and texts results — reducing the burden on your office to locate stock.
3. Have a bridge prescription ready. Consider writing a standing bridge prescription for an alternative strength or formulation that a patient could use in an emergency.
4. Counsel on never stopping abruptly. Reinforce that metoprolol should never be discontinued without a taper, especially in patients with CAD or angina.

Resources for Providers

medfinder offers a provider portal that can help your patients locate their prescriptions at nearby pharmacies without burdening your clinical staff. This is especially valuable for chronic disease patients on essential maintenance medications like metoprolol.